Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Toceranib (PHA 291639E) phosphate is an orally active inhibitor of tyrosine kinase (RTK) receptor, and it potently inhibits PDGFR, VEGFR, and Kit(with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively), has antitumor and antiangiogenic activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | In stock | $ 39.00 | |
25 mg | In stock | $ 59.00 | |
50 mg | In stock | $ 80.00 | |
100 mg | In stock | $ 118.00 |
Description | Toceranib (PHA 291639E) phosphate is an orally active inhibitor of tyrosine kinase (RTK) receptor, and it potently inhibits PDGFR, VEGFR, and Kit(with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively), has antitumor and antiangiogenic activity. |
Targets&IC50 | PDGFRβ:5 nM (ki), Flk-1:6 nM (ki) |
In vivo | Administration of toceranib significantly decreased the number and percentage of Treg in the peripheral blood of dogs with cancer. Dogs receiving toceranib and CYC demonstrated a significant increase in serum concentrations of IFN-γ, which was inversely correlated with Treg numbers after 6 weeks of combination treatment[1]. |
Synonyms | PHA 291639E, SU11654 |
Molecular Weight | 396.46 |
Formula | C22H25FN4O2 |
CAS No. | 356068-94-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 2.4 mg/mL (6.05 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Toceranib 356068-94-5 Angiogenesis Tyrosine Kinase/Adaptors VEGFR PDGFR c-Kit SCFR CD117 SU-11654 Vascular endothelial growth factor receptor inhibit Platelet-derived growth factor receptor Inhibitor PHA 291639E SU 11654 SU11654 inhibitor